SEC Company Response from Elicio Therapeutics, (ELTX) — Mar 12, 2026
Elicio Therapeutics, Inc.
Date: March 12, 2026 · CIK: 0001601485 · Accession: 0001601485-26-000029
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293861
Letter
Document ELICIO THERAPEUTICS, INC. 451 D Street, 5 th Floor Boston, MA 02210 March 12, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: Elicio Therapeutics, Inc. Registration Statement on Form S-3, as amended Filed March 12, 2026 File No. 333-293861 (the “Registration Statement”) Acceleration Request Ladies and Gentlemen: In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Elicio Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date and time of the above-referenced Registration Statement to Monday, March 16, 2026, at 9:00 a.m., Eastern Time, or as soon as thereafter practicable. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please contact Daniel A. Bagliebter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any questions regarding this request. Very truly yours, ELICIO THERAPEUTICS, INC. /s/ Robert Connelly Robert Connelly President and Chief Executive Officer cc: Elicio Therapeutics, Inc. Megan Filoon
Show Raw Text
CORRESP 1 filename1.htm Document ELICIO THERAPEUTICS, INC. 451 D Street, 5 th Floor Boston, MA 02210 March 12, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: Elicio Therapeutics, Inc. Registration Statement on Form S-3, as amended Filed March 12, 2026 File No. 333-293861 (the “Registration Statement”) Acceleration Request Ladies and Gentlemen: In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Elicio Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date and time of the above-referenced Registration Statement to Monday, March 16, 2026, at 9:00 a.m., Eastern Time, or as soon as thereafter practicable. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please contact Daniel A. Bagliebter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any questions regarding this request. Very truly yours, ELICIO THERAPEUTICS, INC. /s/ Robert Connelly Robert Connelly President and Chief Executive Officer cc: Elicio Therapeutics, Inc. Megan Filoon